Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2014

View Archived Issues

Doxofylline receives FDA orphan drug status for bronchiectasis

ONC1-13B shows high efficacy in preclinical models of prostate cancer

ProTide technology applied to anticancer agents to overcome drug resistance

BioAtla grants BioMotiv worldwide rights to IL-22 antibody

Pivotal trial of LDE-225 in advanced basal cell carcinoma meets primary endpoint

CURx Pharmaceuticals enters into license agreement with Gilead Sciences

Phase III ramucirumab lung cancer trial meets primary endpoint of overall survival

Zealand Pharma prepares novel glucagon receptor agonists

Insmed provides interim update from extension study of Arikace in cystic fibrosis

Omeros doses first patient in second phase II trial of OMS-824

Oritavancin NDA accepted by FDA for filing

Researchers at Proximagen present new PAR-2 antagonists

Preclinical results presented for RTL-1000 as a therapeutic agent for stroke

Actavis to acquire Forest Laboratories

Cellceutix submits IND for Prurisol trial, begins enrollment in phase IIb trials of brilacidin

Onconova discloses results from phase III trial of intravenous rigosertib in higher risk MDS

Nerviano Medical Sciences discloses novel JAK inhibitors

Michael J. Fox Foundation awards grant to Ezose Sciences

New H+/K+-ATPase inhibitors designed for gastrointestinal and other disorders

Bayer begins phase III COAST trial of regorafenib

Korean group prepares novel MAbs for cancer

PAK-01 enhances reperfusion and neuroprotection with no hemorrhagic transformation in vivo

Dilafor and Lee's Pharmaceutical sign license agreement for tafoxiparin in China

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...